Study backs efzofitimod as potential pulmonary sarcoidosis treatment
The findings of a new preclinical study in pulmonary sarcoidosis are lending support to the therapeutic potential of efzofitimod, a treatment candidate from Atyr Pharma now being tested in a Phase 3 clinical trial. The researchers found that a protein called HARS-WHEP — whose activity is mimicked by…